GlassScriptPhysician profile
Mackenzie Houser
NPI 1336510163
$7,030.47
in general payments reported to CMS, 2019-2025
44 companies · $4,681 in 2025
The $4,681 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $246 · 2024: $2,104 · 2025: $4,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,313 · Long Term Medical Supply Or Device Loan: $598 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,312.98 |
| Long Term Medical Supply Or Device Loan | $598.20 |
| Education | $119.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,196.64 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,033.77 | 2023-2025 | Enhertu, Imfinzi, Calquence |
| Daiichi Sankyo INC. | $442.35 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $412.91 | 2024-2025 | Erleada, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $412.36 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $354.45 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $255.53 | 2024-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Abbvie INC. | $245.08 | 2024-2025 | |
| Celgene Corporation | $207.64 | 2023-2025 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $204.54 | 2024-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $193.01 | 2024-2025 | |
| Eisai INC. | $179.45 | 2024-2025 | |
| Pfizer INC. | $154.60 | 2024-2025 | |
| Sobi, INC | $134.59 | 2024-2025 | |
| Beone Medicines USA, INC. | $118.91 | 2025 | Brukinsa |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $105.91 | 2024-2025 | Xt Cdx |
| Astellas Pharma US INC | $102.99 | 2024-2025 | Vyloy |
| E.R. Squibb & Sons, L.L.C. | $94.09 | 2025 | Opdivo, Opdualag |
| Genmab U.S., INC. | $93.62 | 2023-2025 | Tivdak, Epkinly |
| Acrotech Biopharma INC. | $87.67 | 2024 | Beleodaq |
| Pharmacosmos Therapeutics INC. | $80.90 | 2024-2025 | Monoferric |
| Stemline Therapeutics INC. | $69.23 | 2024 | Orserdu |
| Emd Serono, INC. | $66.67 | 2024 | |
| Genentech USA, INC. | $60.81 | 2025 | Venclexta, Tecentriq |
| Lilly USA, LLC | $58.62 | 2024 | Verzenio, Retevmo, Jaypirca |
| Karyopharm Therapeutics INC. | $57.52 | 2025 | Xpovio |
| Tersera Therapeutics LLC | $56.99 | 2024-2025 | Zoladex |
| Beigene USA, INC. | $54.30 | 2023-2024 | Brukinsa |
| Recordati_rare_diseases_inc. | $53.83 | 2025 | Enjaymo, Sylvant |
| Glaxosmithkline, LLC. | $51.36 | 2024-2025 | Jemperli, Zejula |
| Puma Biotechnology, INC. | $47.32 | 2024 | |
| Rigel Pharmaceuticals, INC. | $41.53 | 2024 | Rezlidhia, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.03 | 2025 | |
| Alexion Pharmaceuticals, INC. | $38.14 | 2024 | Ultomiris |
| Caris Mpi, INC. | $27.00 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $25.82 | 2025 | |
| Mirati Therapeutics, INC. | $25.70 | 2024 | Krazati |
| Apellis Pharmaceuticals, INC. | $24.55 | 2025 | Empaveli |
| Syndax Pharmaceuticals, INC. | $22.11 | 2025 | Revuforj |
| Novocure INC. | $21.78 | 2025 | Optune Lua (Novottf-200t) |
| Adc Therapeutics America, INC. | $20.75 | 2025 | |
| Myriad Genetic Laboratories, INC. | $20.56 | 2024 | Myrisk |
| Regeneron Healthcare Solutions, INC. | $19.81 | 2025 | Libtayo |
| Springworks Therapeutics, INC. | $16.03 | 2025 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Houser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.